Pfizer (NYSE:PFE) Trading Down 1.9% - Should You Sell?

Key Points

• Pfizer's shares fell by 1.9% to $24.60 during mid-day trading, significantly below the average session volume.
• Analyst ratings include two Strong Buy, four Buy, and eleven Hold, with a consensus target price of $28.12.
• Pfizer reported a quarterly earnings per share of $0.78, exceeding estimates, and plans to pay a dividend of $0.43 on September 2nd, yielding 7.0%.

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) fell 1.9% during mid-day trading on Thursday . The company traded as low as $24.63 and last traded at $24.60. 13,055,456 shares were traded during trading, a decline of 71% from the average session volume of 44,952,574 shares. The stock had previously closed at $25.07.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. Redburn Atlantic dropped their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Jefferies Financial Group upped their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, Leerink Partners dropped their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a 50 day moving average price of $24.76 and a two-hundred day moving average price of $24.40. The company has a market capitalization of $139.84 billion, a P/E ratio of 13.08, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's payout ratio is 91.49%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PFE. Orion Porfolio Solutions LLC increased its holdings in Pfizer by 6.1% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 709,250 shares of the biopharmaceutical company's stock valued at $17,192,000 after purchasing an additional 40,805 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Pfizer by 16.0% during the second quarter. Thrivent Financial for Lutherans now owns 605,236 shares of the biopharmaceutical company's stock worth $14,669,000 after purchasing an additional 83,335 shares during the last quarter. MASTERINVEST Kapitalanlage GmbH acquired a new stake in shares of Pfizer in the second quarter valued at $1,163,000. Silverlake Wealth Management LLC raised its holdings in shares of Pfizer by 10.9% in the second quarter. Silverlake Wealth Management LLC now owns 84,200 shares of the biopharmaceutical company's stock valued at $2,041,000 after buying an additional 8,263 shares during the last quarter. Finally, TT Capital Management LLC lifted its position in Pfizer by 2.8% during the 2nd quarter. TT Capital Management LLC now owns 33,460 shares of the biopharmaceutical company's stock worth $811,000 after buying an additional 922 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.